📰 Alimera Sciences News
Page 2 - Alimera Sciences News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Alimera Sciences. Real-time updates on events, politics, business and more.
March 25, 2024
Investment Analysts’ new coverage for Monday, March 25th: Northland Securities initiated coverage on shares of Astera Labs (NASDAQ:ALAB). The firm issued an outperform rating and a $85.00 price target on the stock. Maxim Group began coverage on shares of Alimera Sciences (NASDAQ:ALIM). Maxim Group issued a buy rating and a $10.00 target price on the […]
February 29, 2024
ATLANTA, Feb. 29, 2024 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (NASDAQ:ALIM) (Alimera), a global pharmaceutical company whose mission is to be invaluable to patients, physicians and partners concerned with retinal
February 22, 2024
This is a year for ophthalmologists to get acclimated with three blockbuster retina drugs approved in 2023, get reacclimated with a returning implant, and to brace for 2025 and beyond.
February 2, 2024
As the proliferative diabetic retinopathy market grows, personalized medicine and research and development will be at the forefront of driving demand....
January 25, 2024
While it may not be enough for some shareholders, we think it is good to see the Alimera Sciences, Inc. ( NASDAQ:ALIM...
January 4, 2024
StockNews.com assumed coverage on shares of Alimera Sciences (NASDAQ:ALIM – Free Report) in a research note released on Sunday. The firm issued a hold rating on the biopharmaceutical company’s stock. Alimera Sciences Price Performance Shares of NASDAQ ALIM opened at $3.90 on Friday. The business has a fifty day moving average price of $3.56 and […]
January 3, 2024
StockNews.com started coverage on shares of Alimera Sciences (NASDAQ:ALIM – Free Report) in a report published on Sunday morning. The brokerage issued a hold rating on the biopharmaceutical company’s stock. Alimera Sciences Price Performance Shares of NASDAQ:ALIM opened at $4.08 on Friday. Alimera Sciences has a 52 week low of $1.30 and a 52 week […]
December 27, 2023
StockNews.com started coverage on shares of Alimera Sciences (NASDAQ:ALIM – Free Report) in a report published on Saturday. The firm issued a hold rating on the biopharmaceutical company’s stock. Alimera Sciences Price Performance Shares of NASDAQ:ALIM opened at $3.81 on Friday. The company’s fifty day moving average price is $3.44 and its 200 day moving […]
December 23, 2023
Analysts’ new coverage for Saturday, December 23rd: StockNews.com began coverage on shares of Aeglea BioTherapeutics (NASDAQ:AGLE). StockNews.com issued a sell rating on the stock. StockNews.com initiated coverage on shares of Ashford (NYSEAMERICAN:AINC). They issued a buy rating on the stock. StockNews.com began coverage on shares of Alimera Sciences (NASDAQ:ALIM). StockNews.com issued a hold rating on […]
December 10, 2023
StockNews.com started coverage on shares of Alimera Sciences (NASDAQ:ALIM – Free Report) in a research report report published on Thursday morning. The firm issued a hold rating on the biopharmaceutical company’s stock. Separately, HC Wainwright reissued a buy rating and set a $5.00 price objective on shares of Alimera Sciences in a report on Monday, […]